All News

pain.jpg

Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction

d Jack Cush, MD

JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

d Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
Muscle (keep)

Immune Necrotizing Myopathy

d Jack Cush, MD

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Read Article
Telemedicine.MD.Computer.phone (keep)

Telemedicine Outcomes in RA Care

d Jack Cush, MD

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

Read Article
FDA.jpg (keep)

FDA Hearing on COVID-19 Vaccines

d Jack Cush, MD

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
burnout work overworked

High Burnout Rates Among Rheumatologists

d Jack Cush, MD

Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.

Read Article
COVID.virus_.corona.jpg (keep)

Remdesivir FDA Approved for Hospitalized COVID-19

d Jack Cush, MD

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article
ACTIV-1 run by the ⁦@NIH⁩ will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?

Links:

Peter Nash drpnash ( View Tweet)

New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37

Links:

Dr. John Cush RheumNow ( View Tweet)

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA

Links:

Dr. John Cush RheumNow ( View Tweet)

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful iTunes https://t.co/FHJv01Sb3a SoundCloud https://t.co/fceBeXGu09

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Back Talk: Taking Calls ^ Questions from Listeners - watch it here>https://t.co/KuTtu5JawO or listen to the Podcast on iTunes> https://t.co/FHJv01AAbC OR SoundCloud> https://t.co/ICukowi11u

Links:

Dr. John Cush RheumNow ( View Tweet)

Population study of 11 million, shows incidence of OPTIC NEURITIS is 3.7 /100K Pt-Yrs. Strongest association with multiple sclerosis (MS) and weaker associations with Behçet disease, sarcoidosis, and Sjögren syndrome. https://t.co/LVw0fcq1F1

Links:

Dr. John Cush RheumNow ( View Tweet)

Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Links:

Dr. John Cush RheumNow ( View Tweet)

How are you consuming Virtual CME Rheumatology conferences

Dr. John Cush RheumNow ( View Tweet)

Working on an Endocarditis for the Rheumatologist podcast. fast facts!!! 1️⃣ 20% no fever 2️⃣ 20% joint pain at presentation 3️⃣ >40% splenomegly 4️⃣ 90% anemia 5️⃣ most common rash = petechiae (Osler node/janeway/Roth spots 10% combined!) #rheumatology #cleclinicrheum #immunology

Adam J Brown AdamJBrownMD ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×